Alvotech (NASDAQ: ALVO), an Iceland-based biotechnology company specializing in biosimilar medicines, has filed its Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission. The company has five approved and marketed biosimilars and nine additional candidates in development across multiple therapeutic areas.

Alvotech announced the publication of its 2025 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The report is available on the SEC website and Alvotech's investor relations page.

Alvotech (NASDAQ: ALVO), an Iceland-based biotechnology company specializing in biosimilar medicines, has published and filed its 2025 Annual Report with the SEC on Form 20-F. The company currently has five approved and marketed biosimilars and nine additional candidates in development across multiple therapeutic areas.

Alvotech (NASDAQ: ALVO), an Icelandic biotech company founded by Róbert Wessman, has filed its Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission. The company focuses on developing and manufacturing biosimilar medications for patients worldwide, with operations spanning major markets including the United States, Europe, Asia, Latin America, Africa, and the Middle East.

Alvotech (NASDAQ: ALVO), an Iceland-based biotechnology company specializing in biosimilar medicines, has filed its Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission. The company has five approved and marketed biosimilars and nine additional candidates in development, supported by a global network of strategic commercial partnerships.

Law firm Kirby McInerney LLP is investigating Alvotech following the company's receipt of a complete response letter from the FDA on November 3, 2025, related to a failed facility inspection in July 2025. The news triggered a significant stock decline of 34.25%, dropping from $7.65 to $5.03 per share. The firm is determining whether securities law violations occurred and is seeking investors to participate in potential litigation.

Alvotech announced a share capital increase of USD 125,000 through the issuance of 12.5 million ordinary shares purchased by its subsidiary at USD 5.2 per share. The shares will be held as treasury shares to support the company's financial obligations including convertible bonds, warrants, and employee compensation. Total issued shares increased from 334 million to 346.5 million, while outstanding shares remained unchanged at 330.3 million.

Alvotech announced the issuance of 12.5 million new shares to its subsidiary at $5.2 per share, increasing treasury stock to support financial obligations including warrants and employee incentives. The company also reported positive top-line results from a pivotal pharmacokinetic study for AVT80, a proposed biosimilar to Entyvio®, meeting all primary endpoints.

Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following the company's November 2, 2025 announcement that the FDA issued a complete response letter for its AVT05 biologics license application, citing manufacturing deficiencies. The stock fell 34% on November 3, 2025, and investors are being encouraged to join a prospective class action lawsuit.

Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following allegations of materially misleading business information. The investigation was triggered after Alvotech received a complete response letter from the FDA on November 2, 2025, regarding deficiencies in its Biologics License Application for AVT05, causing the stock to fall 34% on November 3, 2025. The firm is preparing a class action lawsuit to recover investor losses.

Alvotech announced supply and commercialization agreements with Sandoz for multiple biosimilar candidates in Canada, Australia, and New Zealand. In Canada, the agreement covers one ophthalmology biosimilar as a prefilled syringe, while the Australia and New Zealand agreement encompasses three biosimilar candidates in immunology and gastroenterology. Sandoz will handle regulatory filings and commercialization while Alvotech retains development, clinical activities, and manufacturing responsibilities.

Alvotech announced supply and commercialization agreements with Sandoz for multiple biosimilar candidates in Canada, Australia, and New Zealand. In Canada, the agreement covers one ophthalmology biosimilar as a prefilled syringe, while in Australia and New Zealand, it encompasses three biosimilar candidates in immunology and gastroenterology. Sandoz will handle regulatory filings and commercialization while Alvotech retains development, clinical activities, and manufacturing responsibilities.